Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Raoul Herbrecht(Institut de Cancérologie Strasbourg), Ben de Pauw(Radboud University Medical Center), Richard Sylvester(European Organisation for Research and Treatment of Cancer), Christine M. Durand(University of Maryland, Baltimore), Thomas F. Patterson(National Institute of Allergy and Infectious Diseases), Michael R. Hodges(Pfizer (United States)), J W Oestmann(Charité - Universitätsmedizin Berlin), Paul Stark, Olivier Lortholary(Hôpital Necker-Enfants Malades), Kieren A. Marr(Freedom to Live), Winfried V. Kern(University Medical Center Freiburg), John E. Bennett(National Institute of Allergy and Infectious Diseases), Denis Caillot, Peter F. Troke, David W. Denning(Manchester Academic Health Science Centre), Patricia Ribaud(Hôpital Saint-Louis), Reginald E. Greene, Robert H. Rubin(Massachusetts General Hospital), Eckhard Thiel(Franklin University), Pranatharthi Chandrasekar(Wayne State University), Haran T. Schlamm(Pfizer (United States)), John R. Wingard(University of Florida Health)
Cited by 3,294
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
|Journal of Fungi|2017|2.9k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k